Breaking News Instant updates and real-time market news.

MYGN

Myriad Genetics

$25.55

0.34 (1.35%)

16:59
08/08/17
08/08
16:59
08/08/17
16:59

Myriad Genetics reports Q4 adjusted EPS 30c, consensus 26c

Reports Q4 revenue $200.5M, consensus $193.74M. The company said, "This quarter we saw record demand for hereditary cancer tests and now have 86 percent of our hereditary cancer revenue under long-term contract, providing future stability upon which to build our growing portfolio of new products. Our diversification efforts showed continued success with new products representing greater than two-thirds of test volume and 28 percent of revenue in the fourth-quarter. Our strong progress on transforming the company leaves us well positioned to achieve our long-term strategic goals."

  • 08

    Aug

MYGN Myriad Genetics
$25.55

0.34 (1.35%)

03/13/17
SPHN
03/13/17
UPGRADE
SPHN
Overweight
Myriad Genetics upgraded to Overweight from Equal Weight at Stephens
03/28/17
DBAB
03/28/17
NO CHANGE
Target $15
DBAB
Sell
Zejula label removes upside catalyst for Myriad, says Deutsche Bank
Deutsche Bank analyst Dan Leonard says FDA approval of Tesaro's (TSRO) Zejula, with a "broad rather than biomarker-limited label," removes one potential upside catalyst for Myriad Genetics (MYGN). While some investors are surprised by the broad label, many had already discounted the possibility of a label that limited usage to biomarker positive patients, which would have benefited test-supplier Myriad, Leonard tells investors in a research note. The analyst keeps a Sell rating on Myriad with a $15 price target.
04/05/17
04/05/17
NO CHANGE

Myriad Genetics publishes pivotal studies for myPath melanoma test
Myriad Genetics has published the third clinical validation study and second clinical utility study for its myPath Melanoma test, which completes the reimbursement dossier for the product. The company will submit the reimbursement dossier to Medicare and private insurers three months earlier than expected. myPath Melanoma is an objective genetic test that measures 23 genes to help differentiate malignant melanoma from benign lesions. The third clinical validation was published in the journal Cancer Epidemiology, Biomarkers & Prevention. The study assessed the performance of the myPath Melanoma test in an independent cohort of 182 patients with melanocytic lesions against clinically proven outcomes. The results showed that the myPath Melanoma test had an overall diagnostic accuracy of 95% to effectively differentiate melanoma from benign lesions. The second clinical utility study was designed to evaluate changes in real world patient management based upon the myPath Melanoma test result. Results showed a 71% change in patient management from pre-test recommendations and an 81% reduction in biopsy site re-excisions for patients with a benign test result.
06/29/17
JPMS
06/29/17
NO CHANGE
Target $16
JPMS
Underweight
JPMorgan keeps Underweight rating, $16 target on Myriad Genetics
With the shares up 30% over the past month, JPMorgan analyst Tycho Peterson maintains an Underweight rating on Myriad Genetics with a $16 price target. While the company's pipeline "intriguing," it is not enough to offset a continued decline in the core hereditary cancer business, Peterson tells investors in a research note. He believes near-term catalysts could drive the stock "meaningfully higher or lower," and highlights the FY18 guidance in the Q4 earnings report as being the most significant upcoming event.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.